PhaseBio makes 'extremely difficult' decision to discontinue trial for its experimental Covid-19 therapeutic
October 26, 2020 at 11:50 AM EDT
The new drug candidate will continue to be developed as a potential treatment for pulmonary arterial hypertension.
